RxDoctor Payments Data

Christina Chrisman, MD

Neurology · Phoenix, AZNPI 1578832309

Payments from drug & device makers

$146,315in general payments, 2019–2025

Across 436 payments — averaging $335.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$58K
  • Argenx US, Inc.$31K
  • UCB, Inc.$27K
  • Grifols USA, LLC$10K
  • Grifols Shared Services North America, Inc.$5K
  • Biogen$5K
  • plus $10K from 41 others

What the payments were for

  • Consulting fees$33,30823%
  • Speaking & faculty fees$90,37062%
  • Travel & lodging$8,4056%
  • Food & beverage$14,05410%
  • Education$1780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,315 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$35,462
Medicare patients
146
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz11$811,664
Gamunex-CImmune Globul G/Gly/Iga Avg 4696$789,292
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc12$737,273
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5039$655,930
SolirisEculizumab21$535,427
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5040$461,524
EvrysdiRisdiplam15$407,884
GammakedImmune Globul G/Gly/Iga Avg 4615$332,554
BivigamImmun Glob G(Igg)/Gly/Iga Ov5018$105,319
Pyridostigmine Bromide59$5,456
Mycophenolate Mofetil26$4,467
Pregabalin85$2,209
Azathioprine20$1,739
Gabapentin62$986
Prednisone115$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris, Soliris$57,901$1,347,09232 claims
Grifols USA, LLCGamunex-C$10,099$789,29296 claims
Argenx US, Inc.Vyvgart Hytrulo$31,365$737,27312 claims
CSL BehringPrivigen$3,148$461,52440 claims
Genentech USA, Inc.Evrysdi$2,291$407,88415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →